We are live on ! Find out more
IMVT icon

Immunovant
IMVT

94 hedge funds and large institutions have $157M invested in Immunovant in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 31 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

299% more call options, than puts

Call options by funds: $2.51M | Put options by funds: $629K

0.46% more ownership

Funds ownership: 33.98% → 34.45% (+0.46%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 31

16% less funds holding

Funds holding: 112 → 94 (-18)

21% less capital invested

Capital invested by funds: $197M → $157M (-$40.5M)

54% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 26

Holders
94
Holders Change
-18
Holders Change %
-16.07%
% of All Funds
1.58%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
12
Increased
31
Reduced
31
Closed
26
Calls
$2.51M
Puts
$629K
Net Calls
+$1.88M
Net Calls Change
-$4.46M

Top Buyers

1
DTC
Deep Track Capital
Connecticut
+$9.63M
2
AGM
Alpine Global Management
New York
+$2.53M
3
BlackRock
BlackRock
New York
+$1.2M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$1.1M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$1.01M

Top Sellers

1
OCA
Octagon Capital Advisors
New York
-$3.87M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$2.53M
3
MP
Mangrove Partners
Connecticut
-$2.03M
4
PAMP
Polar Asset Management Partners
Ontario, Canada
-$1.92M
5
Two Sigma Investments
Two Sigma Investments
New York
-$1.17M
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$622K -$295K -68,351 -30%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$552K -$23.2K -5,366 -4%
PP
28
PDT Partners
New York
$527K – – –
AG
29
Algert Global
California
$492K -$43.7K -10,127 -7%
HSBC Holdings
30
HSBC Holdings
United Kingdom
$486K +$53.9K +12,481 +11%
Citadel Advisors
31
Citadel Advisors
Florida
$429K -$495K -114,586 -51%
Swiss National Bank
32
Swiss National Bank
Switzerland
$371K – – –
WP
33
Woodline Partners
California
$359K +$398K +92,100 New
NYLIM
34
New York Life Investment Management
New York
$330K +$366K +84,635 New
AllianceBernstein
35
AllianceBernstein
Tennessee
$326K +$15.1K +3,500 +4%
MAM
36
Martingale Asset Management
Massachusetts
$274K +$56 +13 +0%
AA
37
ALPS Advisors
Colorado
$270K -$218K -50,515 -42%
PI
38
PEAK6 Investments
Illinois
$247K +$56.2K +13,000 New
Group One Trading
39
Group One Trading
Illinois
$246K +$25.6K +5,937 +10%
RhumbLine Advisers
40
RhumbLine Advisers
Massachusetts
$227K +$54.9K +12,711 +28%
BCM
41
BCK Capital Management
Connecticut
$212K – – –
UBS AM
42
UBS AM
Illinois
$203K – – –
California State Teachers Retirement System (CalSTRS)
43
California State Teachers Retirement System (CalSTRS)
California
$198K -$2.54K -589 -1%
Allspring Global Investments
44
Allspring Global Investments
North Carolina
$191K +$212K +49,161 New
PNC Financial Services Group
45
PNC Financial Services Group
Pennsylvania
$178K -$566 -131 -0.3%
GCP
46
GSA Capital Partners
United Kingdom
$155K +$172K +39,817 New
CS
47
Credit Suisse
Switzerland
$145K +$9.24K +2,140 +6%
DCM
48
Dupont Capital Management
Delaware
$133K +$39.1K +9,055 +36%
DekaBank Deutsche Girozentrale
49
DekaBank Deutsche Girozentrale
Germany
$132K – – –
VEA
50
Virtus ETF Advisers
New York
$118K +$38.8K +8,984 +42%
1
2
3 4 5

IMVT Hedge Fund Activity: Q2 2022 in Review

94 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q2 2022, worth a combined $157M — down 21% from $197M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of IMVT and 12 opened new positions — a net loss of 14 holders — while 31 trimmed existing stakes and 31 added.

The largest buyer was Deep Track Capital, adding an estimated $9.63M. The largest seller was Octagon Capital Advisors, cutting an estimated $3.87M.

  • 94 institutional investors held Immunovant (IMVT) as of Q2 2022, down from 112 in Q1 2022.
  • Funds reported $157M of Immunovant stock for Q2 2022, down 21% quarter-over-quarter.
  • 12 funds opened new Immunovant positions in Q2 2022 and 26 closed out, a net change of -14 holders.
  • The largest Immunovant buyer in Q2 2022 was Deep Track Capital, an estimated $9.63M added.
  • The largest Immunovant seller in Q2 2022 was Octagon Capital Advisors, an estimated $3.87M sold.

Based on aggregated 13F filings for Q2 2022.